Key result
Systemic lupus erythematosus-specific inflammatory factors, such as type I interferons, contribute to up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease.
Patients with systemic lupus erythematosus have up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease. Recent advances in the etiology of vascular damage in this disease stress the interplay of lupus-specific inflammatory factors with traditional cardiac risk factors, leading to increased endothelial damage. This review analyzes the putative role that immune dysregulation and lupus-specific factors may play in the pathogenesis of premature vascular damage in this disease. The potential role of various cytokines, in particular type I interferons, in the development of accelerated atherosclerosis is examined. Potential therapeutic targets are discussed.
No takes yet. Share an insight, caveat, or question.
Kahlenberg et al. (2010) conducted a review in Systemic lupus erythematosus and atherosclerotic cardiovascular disease. Lupus-specific inflammatory factors and immune dysregulation (e.g., type I interferons) was evaluated on Atherosclerotic cardiovascular disease and premature vascular damage. Systemic lupus erythematosus-specific inflammatory factors, such as type I interferons, contribute to up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: